Mereo BioPharma (MREO) Research & Development (2023 - 2026)

Mereo BioPharma (MREO) has reported Research & Development for 4 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 66.35% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $15.0 million, a 29.47% decrease from a year earlier, with the FY2025 full-year figure at $17.8 million, down 15.12% from the prior year.
• Research & Development was $1.8 million for Q2 2026 at Mereo BioPharma, down from $4.7 million in the prior quarter.
• Over five years, Research & Development peaked at $8.8 million in Q4 2024 and troughed at $1.8 million in Q2 2026.
• A 4-year average of $4.5 million and a median of $4.2 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 83.62% in 2024 and tumbled 66.35% in 2026, its largest moves.
• Over 4 years, Research & Development stood at $4.8 million in 2023, then surged by 83.62% to $8.8 million in 2024, then sank by 52.47% to $4.2 million in 2025, then slumped by 56.88% to $1.8 million in 2026.
• The last three Research & Development figures came in at $1.8 million (Q2 2026), $4.7 million (Q1 2026), and $4.2 million (Q4 2025), per Business Quant data.